13 Oct 2026, 10:04 IST
Apollo Hospitals Enterprise Limited
HDFC Securities · BUY
The report estimates a Sales/EBITDA impact of 0.5%/2.8% from the oncology drug price cap and maintains a BUY rating.
From Healthcare Services Sector Update Oct26 HSIE, written by HDFC Securities. Orivam summarised it; the view is HDFC Securities's, not Orivam's.
Open the original PDF →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.